Market capitalization | €20.00k |
Enterprise Value | €-3.20m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.25 |
EV/Sales (TTM) EV/Sales | -7.11 |
P/S ratio (TTM) P/S ratio | 0.04 |
P/B ratio (TTM) P/B ratio | 0.31 |
Sales growth (TTM) Sales growth | -92.80% |
Turnover (TTM) Turnover | €450.00k |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Epigenomics:
1 Analyst has issued a forecast Epigenomics:
Jun '23 |
+/-
%
|
||
Turnover | 0.45 0.45 |
93%
93%
|
|
Gross income | -1.88 -1.88 |
134%
134%
|
|
EBITDA | -12 -12 |
100%
100%
|
EBIT (operating result) EBIT | -15 -15 |
119%
119%
|
Net profit | -16 -16 |
470%
470%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany.
Head office | Germany |
CEO | Gregory Hamilton |
Employees | 34 |
Founded | 1997 |
Website | www.epigenomics.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.